Delegates convening in San Francisco Monday for the most important week of the year for the biotechnology sector will certainly be looking to presentations from industry executives and leaders at the 37th annual J.P. Morgan Healthcare Conference for important clues as to what the year ahead might hold for them and the strategies that will be needed to navigate what is likely to be a very challenging 12 months. The sector has just come off a terrible fourth quarter as investors shied away from biopharma company equities big time. As a result, the BioWorld Biopharmaceutical Index slipped 11 percent in value during this period.